Literature DB >> 11394511

Perioperative medical management and outcome following thymectomy for myasthenia gravis.

C Chevalley1, A Spiliopoulos, M de Perrot, J M Tschopp, M Licker.   

Abstract

PURPOSE: To describe the evolution of the perioperative management of myasthenia gravis (MG) patients undergoing thymectomy and to question the need for systematic postoperative ventilation. CLINICAL FEATURES: We collected data retrospectively from 36 consecutive MG patients who underwent thymectomy over a 21-yr period, via transthoracic, -cervical or -sternal incisions (n=5, n=7, n=24, respectively). From 1980 to 1993, a balanced anesthetic technique (n=24) included various inhalational agents with opiates and myorelaxants (in eight cases); 22 patients were admitted to the intensive care unit (ICU). Since 1994, i.v. propofol was combined with epidural bupivacaine and sufentanil (n=12); all patients were admitted to the postanesthesia care unit. Short-term postoperative ventilation (median time four hours, range from three to 48 hr) was required in eight patients who had longer hospital stay (median stay=12 days, range (8-28) vs five days (4-15) for patients with early extubation, P <0.05) but similar clinical improvement six months after thymectomy. Postoperative ventilatory support was required more frequently when a balanced anesthetic technique was used (odds ratio=4.2 (1.1-9.7), P=0.03) and particularly when myorelaxants were given (odds ratio=13.9 (2.1-89.8), P=0.009). Leventhal's scoring system had low sensitivity (22.2%) and positive predictive values (25%).
CONCLUSIONS: Our data show that the severity of MG failed to predict the need for postoperative ventilation. A combined anesthetic technique was a safe and cost-effective alternative to balanced anesthesia as it provided optimal operating conditions and resulted in fewer admissions in ICU and shorter hospital stays.

Entities:  

Mesh:

Year:  2001        PMID: 11394511     DOI: 10.1007/BF03028306

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  6 in total

1.  Estimation of the success rate of anesthetic management for thymectomy in patients with myasthenia gravis treated without muscle relaxants: a retrospective observational cohort study.

Authors:  Yoshihito Fujita; Satoru Moriyama; Satoshi Aoki; Saya Yoshizawa; Maiko Tomita; Taiki Kojima; Yukiko Mori; Naoko Takeuchi; Min-Hye So; Motoki Yano; Kazuya Sobue
Journal:  J Anesth       Date:  2015-03-22       Impact factor: 2.078

2.  Thymectomy for Myasthenia Gravis.

Authors:  Gary S. Gronseth; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.598

3.  The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis.

Authors:  Amel Meraouna; Geraldine Cizeron-Clairac; Rozen Le Panse; Jacky Bismuth; Frederique Truffault; Chantal Tallaksen; Sonia Berrih-Aknin
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

4.  Preoperative risk factors for prolonged postoperative ventilation following thymectomy in myasthenia gravis.

Authors:  Weihua Lu; Tao Yu; Federico Longhini; Xiaogan Jiang; Xuemei Qin; Xiaoju Jin
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  Anesthesia for patients undergoing transsternal thymectomy for juvenile myasthenia gravis.

Authors:  Lianne Stephenson; Igor Tkachenko; Robert Shamberger; Christian Seefelder
Journal:  Saudi J Anaesth       Date:  2011-01

6.  Myasthenic crisis and late deep vein thrombosis following thymectomy in a patient with myasthenia gravis: A case report.

Authors:  Cheng-Yuan Lin; Wei-Cheng Liu; Min-Hsien Chiang; I-Ting Tsai; Jen-Yin Chen; Wan-Jung Cheng; Chun-Ning Ho; Shu-Wei Liao; Chin-Chen Chu; Cheuk-Kwan Sun; Kuo-Chuan Hung
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.